The CagriSema trials used 2.4 mg as the target, and the Phase 3 monotherapy data also used 2.4 mg
Customize your own product packaging box Our packaging boxes can be customized in size, structure, and materials to meet your specific product display and protection needs
However, they can also come from petechiae, infection, medication reaction, platelet problems, or changing skin growths
Once the mechanism works, the question shifts from who can build it to who controls it, and that's where most teams are underprepared." Across the landscape: Novo Nordisk is building across multiple triple-agonist assets Pfizer has entered through acquisition Hanmi is advancing the only clinical-stage small-molecule triple Innovent, Hengrui, and multiple Chinese sponsors are scaling pipeline depth Sanofi holds the largest IP position without a disclosed asset 27 programs
The maximum retatrutide dose currently being studied in major Phase 3 obesity trials is 12mg once weekly
While they're both injectable forms of Semaglutide, they come in different doses